Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04317105
Title Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)

Advanced Solid Tumor


Copanlisib + Ipilimumab + Nivolumab

Copanlisib + Nivolumab

Age Groups: adult | senior
Covered Countries USA | CAN

Facility Status City State Zip Country Details
Dana-Farber Cancer Institute Active, not recruiting Boston Massachusetts 02215 United States Details
University of Texas at Austin Recruiting Austin Texas 78712 United States Details
University of Texas Medical Branch Recruiting Galveston Texas 77555-0565 United States Details
M D Anderson Cancer Center Recruiting Houston Texas 77030 United States Details
Virginia Commonwealth University/Massey Cancer Center Recruiting Richmond Virginia 23298 United States Details
University Health Network-Princess Margaret Hospital Recruiting Toronto Ontario M5G 2M9 Canada Details
*Shaded cells indicate that there was no data available from for the field